Moody’s assigns ‘A2’ rating to University of Maryland Medical System’s bonds

Moody’s Investors Service assigned an “A2” rating to Baltimore-based University of Maryland Medical System’s proposed $159.6 million of series 2017B bonds and $122.6 million of series 2017C bonds.

Advertisement

The rating assignment is based on a number of factors, including UMMS’ solid market share and strong position as the clinical training venue for Baltimore-based University of Maryland School of Medicine.

The outlook is stable, reflecting Moody’s Investors Service’s expectation that UMMS will continue to generate stable margins.

More articles on healthcare finance:
ACA repeal would trigger $166B loss for hospitals by 2026 — 3 things to know from AHA, FAH
6 experts share healthcare RCM predictions for 2017
Fitch issues stable outlook for US healthcare

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.